IFNA2 and glioblastoma: The co-formulation of IFN-α2b and IFN-γ in synergic proportions, known as HeberFERON, has been approved for the treatment of skin baso-cellular carcinoma but has also been used off-label for other types of cancers, including glioblastoma [5].